Figures

**Figure 1. **Elevation of plasma zinc after 14 days of 50 mg supplemental Zn per day. Results shown represent the mean ± standard error of the mean. A group of n = 10 healthy control, test subjects had a blood sample taken 12 hours after their final Zn dose. A second group (n = 5), also healthy controls, had their blood sample taken only 2 hours after their final Zn dose. ^{*}P < 0.005 (paired Student’s t test); ^{**}P < 0.01 against their own pre-zinc supplement plasma Zn values.

**Figure 2. **Lack of effect of Zn supplementation on plasma copper levels. A group of n = 10 healthy control, test subjects had their blood sample taken 12 hours after their final Zn dose. P = 0.35 (paired Student’s t). Not significant. Data shown represent mean ± standard error of the mean.

**Figure 3. **Effect of PPI use on percentage change in plasma zinc levels after zinc supplementation. The increase in plasma zinc levels after 14 days of 53.2 mg/day zinc supplementation was measured for n = 5 healthy control test subjects versus n = 5 reflux-disease patients on long-term PPI therapy. Data shown represent the mean percentage increase ± the standard error of the mean. P < 0.01 (paired Student’s t test).

**Figure 4. **The effect of chronic PPI use on plasma zinc levels. Plasma zinc levels (mcg/dL) were measured in a group of 10 test subjects on long-term PPI medication (as described in Methods) and a matched group of 10 healthy control test subjects not taking PPI, antacid or H2 blocker medication. For the healthy control group, the mean (±standard error of the mean) was 91 mcg/dL ± 3 and the mean for the PPI-group was 75 mcg/dL ± 3 (Paired Student’s t test, P = 0.004).

Table

**Table 1. **Demographic Data

| Study 1 (n = 15) | Study 2 (n = 5) | Study 3 (n = 10) |
---|

Controls | Controls | PPI users | Controls | PPI Users |
---|

n | % | n | % | n | % | n | % | n | % |
---|

^{*}Barretts, Hemochromatosis. |

Age (years) | | | | | | | | | | |

18 – 30 | 5 | 33.3 | 3 | 60 | 3 | 60 | 6 | 60 | 2 | 20 |

31 - 40 | 2 | 13.3 | 1 | 20 | 1 | 20 | 2 | 20 | 1 | 10 |

41 – 50 | 4 | 26.7 | 0 | 0 | 1 | 20 | 0 | 0 | 4 | 40 |

51 – 60 | 2 | 13.3 | 1 | 20 | 0 | 0 | 2 | 20 | 3 | 30 |

> 60 | 2 | 13.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

Gender | | | | | | | | | | |

Male | 5 | 33.3 | 1 | 20 | 1 | 20 | 5 | 50 | 4 | 40 |

Female | 10 | 66.7 | 4 | 80 | 4 | 80 | 5 | 50 | 6 | 60 |

Ethnicity | | | | | | | | | | |

Caucasian | 13 | 86.7 | 4 | 80 | 5 | 100 | 7 | 70 | 9 | 90 |

Asian | 2 | 13.3 | 1 | 20 | 0 | 0 | 3 | 30 | 0 | 0 |

African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 10 |

Type of PPI | | | | | | | | | | |

n/a | | | | | | | | | | |

Protonix | | | | | 0 | 0 | | | 3 | 30 |

Prilosec | | | | | 2 | 40 | | | 4 | 40 |

Nexium | | | | | 1 | 20 | | | 1 | 10 |

Aciphex | | | | | 1 | 20 | | | 2 | 20 |

Prevacid | | | | | 1 | 20 | | | 0 | 0 |

PPI Duration | | | | | | | | | | |

n/a | | | | | | | | | | |

6 months-2 years | | | | | | | | | 4 | 40 |

> 2 years | | | | | | | | | 6 | 60 |

GI Disease | | | | | | | | | | |

GERD | 3 | 20 | | | 5 | 100 | 0 | 0 | 9 | 90 |

Other | 0 | 0 | | | 0 | 0 | 0 | 0 | 1* | 10 |

None | 12 | 80 | | | 0 | 0 | 10 | 100 | | 0 |